Indeed, these drugs might control the interactions of tumour and non-tumor cells leading to activation of PI3K and its effectors, such as the crosstalk triggered in the context of young cases of ATLL patients harbouring CTLA4-CD28 fusion [38]. This evidence concerns the gene CTLA4 and adult T-cell leukemia/lymphoma.